detorubicin and Neoplasms

A phase II trial of detorubicin (DTR) has been conducted on 164 patinets with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of breast carcinoma patients, in 17% of head and neck carcinoma patients and of melanoma patients, and in 6% of ureri cervic carcinoma patients. DTR seems as toxic as adriamycin on bone marrow and the heart and might induce a little less alopecia.

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasms; Uterine Neoplasms

This report concerns the experimental activity and the preliminary clinical results obtained with detorubicin, an anthracycline. Experimentally, in comparison with doxorubicin, detorubicin is less toxic, less immunodepressive, and less mutagenic, its experimental antitumor activity is equal or superior, and differences are found in pharmacokinetics. Its most interesting activities in clinical cancer therapy are found in non-Hodgkin lymphomas, in carcinomas, and in soft-tissue sarcomas.

Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Mice; Mutagens; Neoplasms; Neoplasms, Experimental

A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of the breast carcinoma patients, in 17% of the head and neck carcinoma patients and melanoma patients, and in 6% of the uteri cervix carcinoma patients. DTR seems to be as toxic as adriamycin for bone marrow and heart, but might induce a little less alopecia.

Topics: Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Humans; Neoplasms